The experimental cancer drug ibrutinib has wowed in clinical trials, beating deadly blood cancers without the painful side effects of currently approved therapies.
And it has raced through development and regulatory hurdles, in part thanks to a US program to accelerate the development of particularly promising drugs, says its developer Pharmacyclics, based in Sunnyvale, California.
The US Food and Drug Administration (FDA) launched the ‘breakthrough therapy’ designation in 2012, and the label has been eagerly embraced by the pharmaceutical industry. Recent months have seen a steady stream of drugs being submitted for review. For some firms — particularly young ones — the designation can bring an extra boost of cash by raising investor confidence.
But for all the fanfare, the industry is also watching closely to see exactly what benefits can be gained by having a drug reviewed through this route. “It’s like winning a beauty pageant,” says Timothy Coté, a former director of the FDA’s Office of Orphan Products Development who now runs a consultancy called Coté Orphan Consulting in Silver Spring, Maryland. “It doesn’t have specific tangible outcomes, but it does appear to have enlivened the community.”
The breakthrough therapy designation was created by the FDA Safety and Innovation Act, a law that requires the agency to fast-track promising drugs for serious or life-threatening conditions. The FDA aims to do this by meeting early and often with developers, as well as working with them to design clinical trials that deliver the needed data quickly and efficiently.
The industry leapt on the opportunity, so far submitting 99 applications for the designation. But the flurry of applications may partly be a product of confusion, says Coté: the FDA has avoided laying out detailed descriptions of what constitutes a breakthrough, and some companies are unsure of the criteria. “Most biotech chief executives with something in the clinic think that they’re already there,” Coté says — but 47 of the applications submitted in the past year have been denied. In most cases the denials are due to insufficient clinical data, the FDA says.
The Latest on: Fast-Track Drugs
- Sterile Injectable Drugs Market Predicted to Reach US$ 657 Bn by 2024 on February 23, 2019 at 6:33 am
The report highlights a growing trend of small molecule injectable drugs gaining immense popularity. Moreover, fast-track FDA approvals for injectable drugs, increasing demand for injectable drug deli... […]
- Osteoarthritis Drug Receives Fast Track Designation from FDA on February 22, 2019 at 5:52 am
n late November 2018, the FDA announced that it was granting Fast Track designation to an investigational drug for the treatment of osteoarthritis (OA). The drug, developed by Galapagos, is known by i... […]
- Neurelis Announces That Intravail® Licensee ARS Pharmaceuticals Intranasal Epineprhine Program Given Fast Track Designation on February 20, 2019 at 6:40 am
ARS Pharmaceuticals announced that ARS-1, an intranasal epinephrine spray in development to treat severe allergic reactions, was granted Fast Track designation by the U.S. Food and Drug Administration ... […]
- ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug on February 20, 2019 at 4:42 am
The Gencaro development program has been granted Fast Track designation by FDA ... risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products ... […]
- Fast track for AbbVie drug • Zell bets on health tech • Sterigenics sues Illinois EPA on February 20, 2019 at 3:15 am
FDA TO GIVE ABBVIE ARTHRITIS DRUG PRIORITY REVIEW: North Chicago-based AbbVie said the U.S. Food and Drug Administration granted priority review to its New Drug Application (NDA) for upadacitinib, an ... […]
- ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray on February 19, 2019 at 5:32 pm
today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ARS-1, an investigational intranasal epinephrine spray that could provide an easy-to-use ... […]
- Intranasal Epinephrine Spray Granted Fast Track Designation on February 19, 2019 at 10:56 am
ARS-1 is an aqueous formulation of epinephrine nasal spray developed with novel nasal absorption enhancing technology The Food and Drug Administration (FDA) has granted Fast Track status to ARS-1 (ARS ... […]
- ‘Tumour monorail’ on the fast track for human trials on February 15, 2019 at 4:10 pm
“It was also the first demonstration of bringing the tumour to your drug rather than your drug going into the ... on rats but its designation as a Breakthrough Device should fast-track approval for us... […]
- RDD Pharma Receives Fast Track Designation from FDA for RDD-0315 for Treatment of Fecal Incontinence in Spinal Cord Injury Patients on February 14, 2019 at 3:00 am
Fast track is a designation by the FDA for an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical ... […]
- MMJ Files FDA Fast Track Approval Application For Cannabis Multiple Sclerosis Drug on February 13, 2019 at 1:47 am
FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill an unmet medical need. MMJ International ... […]
via Google News and Bing News